DVA
NYSEMulti-factor composite percentile ranking across peer cohort fundamentals.
DVA — composite score 85/100, grade A+. Fair-value band: $48.71 (-72.7% premium).
Cross-sectional ranking across covered U.S. equities
Standalone corporate health, ROIC & margins from SEC filings.
Consensus of active sell-side institutional brokers.
Consensus comparison requires a reported analyst recommendation breakdown.
1-Year Price Performance
Range: 1D · 5D · 1M · 6M · YTD · 1Y · 5Y · ALL
Wall Street Consensus Rating
Sell-side broker recommendations & 12-month target status
Decision Read unavailable
Vantage could not load price history for dva, so trend, momentum, RSI, and moving averages — the tactical half of the verdict — cannot be computed. No verdict is asserted.
Investor context
DVA appears discounted on valuation multiples, but underlying margin compression and weak Piotroski scoring suggest an active value trap.
Health Care, Biotech & Pharmaceuticals Decision Playbook(DVA)
Standard multiples break when applied uniformly across Health Care equities. Vantage quant models calibrate specialized valuation anchors, solvency thresholds, and tailored execution rules for Day Traders, Short-Term Swing Traders, and Long-Term Investors.
Relative 4-factor momentum & valuation for swing traders paired with standalone 6-factor fundamental corporate health for long-term compounders.
Multi-timeframe moving averages (SMA 20/50/200), RSI, and tactical entry signals.
Peer valuation multiples, revenue growth horizons, capital efficiency & solvency.
Sector Peer Cohort
Auto-generated from Vantage peer set